Overview

NAL ER IPF Respiratory Function and Safety Study

Status:
RECRUITING

Trial end date:
2025-10-01

Target enrollment:

Participant gender:

Summary

The primary purpose of this study is to assess the safety and tolerability of escalating doses of NAL ER and to evaluate its effect on respiratory function in participants with IPF.

Phase:

PHASE1

Details

Lead Sponsor:

Trevi Therapeutics

Treatments:

Nalbuphine